Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Non Operating Income (2018 - 2025)

X4 Pharmaceuticals' Non Operating Income history spans 8 years, with the latest figure at -$2.3 million for Q3 2025.

  • For Q3 2025, Non Operating Income fell 7.11% year-over-year to -$2.3 million; the TTM value through Dec 2025 reached $6.9 million, down 62.57%, while the annual FY2025 figure was -$753000.0, 1.89% down from the prior year.
  • Non Operating Income reached -$2.3 million in Q3 2025 per XFOR's latest filing, down from -$547000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $19.7 million in Q2 2024 to a low of -$2.3 million in Q3 2025.
  • Average Non Operating Income over 5 years is $1.3 million, with a median of $105000.0 recorded in 2024.
  • The largest YoY upside for Non Operating Income was 9676.24% in 2024 against a maximum downside of 12929.41% in 2024.
  • A 5-year view of Non Operating Income shows it stood at $2.8 million in 2021, then plummeted by 150.54% to -$1.4 million in 2022, then soared by 114.72% to $212000.0 in 2023, then surged by 230.19% to $700000.0 in 2024, then tumbled by 433.71% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Non Operating Income are -$2.3 million (Q3 2025), -$547000.0 (Q2 2025), and $9.8 million (Q1 2025).